Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Chue

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
Expert Opinion on Pharmacotherapy|July 23, 2016
How can the new antipsychotic medications improve quality of life in patients with schizophrenia?Pierre Chue
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|October 27, 2004
Gabapentin treatment for premature ejaculationPierre Chue
Journal of Psychopharmacology (Oxford, England)|October 19, 2006
The relationship between patient satisfaction and treatment outcomes in schizophreniaPierre Chue
Neuropsychiatric Disease and Treatment|March 21, 2009
Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychoticPierre Chue
Expert Review of Neurotherapeutics|October 9, 2009
Risperidone long-acting injectionPierre Chue
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|April 23, 2004
The assessment and management of antipsychotic-associated metabolic disturbances from a psychiatric perspectivePierre Chue
Acta Neuropsychiatrica|March 18, 2016
Compliance and convenience: do physicians and patients see depot medication differently?Pierre Chue
Evidence-Based Nursing|November 22, 2013
In adults with intellectual disability, discontinuation of antipsychotics is associated with reduction in weight, BMI, waist circumference and blood pressurePierre Chue
Current Pharmaceutical Design|December 1, 2012
Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1)Pierre Chue
Evidence-Based Nursing|January 23, 2025
Investigating the correlations between a history of personal trauma and secondary traumatic stress symptoms in mental health professionalsPierre Chue, Moriah Tate
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
Expert Opinion on Pharmacotherapy|July 23, 2016
How can the new antipsychotic medications improve quality of life in patients with schizophrenia?Pierre Chue
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|October 27, 2004
Gabapentin treatment for premature ejaculationPierre Chue
Journal of Psychopharmacology (Oxford, England)|October 19, 2006
The relationship between patient satisfaction and treatment outcomes in schizophreniaPierre Chue
Neuropsychiatric Disease and Treatment|March 21, 2009
Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychoticPierre Chue
Expert Review of Neurotherapeutics|October 9, 2009
Risperidone long-acting injectionPierre Chue
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|April 23, 2004
The assessment and management of antipsychotic-associated metabolic disturbances from a psychiatric perspectivePierre Chue
Acta Neuropsychiatrica|March 18, 2016
Compliance and convenience: do physicians and patients see depot medication differently?Pierre Chue
Evidence-Based Nursing|November 22, 2013
In adults with intellectual disability, discontinuation of antipsychotics is associated with reduction in weight, BMI, waist circumference and blood pressurePierre Chue
Current Pharmaceutical Design|December 1, 2012
Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1)Pierre Chue
Evidence-Based Nursing|January 23, 2025
Investigating the correlations between a history of personal trauma and secondary traumatic stress symptoms in mental health professionalsPierre Chue, Moriah Tate
Pageof 8